Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listMethadone hydrochloride

Methadone hydrochloride

Synonym(s):6-Dimethylamino-4,4-diphenylheptan-3-one hydrochloride

  • CAS NO.:1095-90-5
  • Empirical Formula: CH3ClO
  • Molecular Weight: 66.49
  • MDL number: MFCD00058014
  • EINECS: 214-140-7
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2023-06-08 09:03:05
Methadone hydrochloride Structural

What is Methadone hydrochloride?

Description

(±)-Methadone (hydrochloride) (Item No. ISO00145) is an analytical reference material categorized as an opioid. (±)-Methadone has analgesic activity. Formulations containing (±)-methadone have been used in the treatment of opioid addiction. (±)-Methadone is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications.

Chemical properties

White Solid

Originator

Dolophine ,Lilly,US,1947

The Uses of Methadone hydrochloride

Controlled substance (opiate). Methadone hydrochloride is used in treatment of opioid dependence.

Definition

A synthetic narcotic.

Manufacturing Process

Diphenylacetonitrile is condensed with 2-chloro-1-dimethylaminopropane to give 4-(dimethylamino)-2,2-diphenyl valeronitrile. It is then reacted with ethyl magnesium bromide and then hydrolyzed using HCl to give methadone hydrochloride.

brand name

Dolophine Hydrochloride (Roxane); Dolophine Hydrochloride (Xanodyne); Methadose (Mallinckrodt); Westadone (Sandoz).

Therapeutic Function

Narcotic analgesic

Hazard

Toxic. Addictive narcotic. Use restricted.

Clinical Use


Treatment of opioid drug addiction
Analgesic for moderate to severe pain

Drug interactions

Metabolised in the liver to the Potentially hazardous interactions with other drugs Analgesics: possible opioid withdrawal with buprenorphine and pentazocine. Antibacterials: metabolism increased by rifampicin; increased risk of ventricular arrhythmias with delamanid and telithromycin. Antidepressants: concentration possibly increased by fluoxetine, fluvoxamine, paroxetine and sertraline; possible CNS excitation or depression with MAOIs and moclobemide - avoid; possibly increased sedative effects with tricyclics; concentration possibly reduced by St John's wort. Antiepileptics: concentration reduced by carbamazepine, phenobarbital and phenytoin. Antifungals: concentration increased by fluconazole, ketoconazole, voriconazole and possibly itraconazole - may need to reduce methadone dose with voriconazole, avoid with ketoconazole. Antihistamines: increased sedative effects with sedating antihistamines.
Antimalarials: increased risk of ventricular arrhythmias with piperaquine with artenimol - avoid.
Antipsychotics: enhanced hypotensive and sedative effects; increased risk of ventricular arrhythmias with antipsychotics that prolong the QT interval - avoid with amisulpride.
Antivirals: methadone possibly increases
concentration of zidovudine; concentration reduced by efavirenz, fosamprenavir and ritonavir; concentration possibly reduced by abacavir, nevirapine and rilpivirine; concentration possibly affected by boceprevir; concentration of didanosine possibly reduced; increased risk of ventricular arrhythmias with saquinavir and telaprevir - avoid with saquinavir and use with caution with telaprevir.
Atomoxetine: increased risk of ventricular arrhythmias.
Cytotoxics: possible increased risk of ventricular arrhythmias with bosutinib, ceritinib, panobinostat and vandetanib.
Dopaminergics: avoid with selegiline.
Nalmefene: avoid concomitant use.
Sodium oxybate: enhanced effect of sodium oxybate - avoid

Metabolism

Metabolised in the liver to the major metabolite 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine and the minor metabolite 2-ethyl-3,3-diphenyl-5- methylpyrrolidine, both of them inactive. Two other metabolites have also been identified. These metabolites are excreted in the faeces and urine with unchanged methadone

Purification Methods

The salt crystallises from EtOH, or EtOH/Et2O.

Properties of Methadone hydrochloride

Melting point: 232-2340C
Density  1.0103 (rough estimate)
refractive index  1.5790 (estimate)
Flash point: 11 °C
storage temp.  2-8°C
solubility  Soluble in water, freely soluble in ethanol (96 per cent)
form  powder
color  white to off-white
Water Solubility  120 mg/mL
Stability: Stable. Incompatible with strong oxidizing agents.
CAS DataBase Reference 1095-90-5(CAS DataBase Reference)

Safety information for Methadone hydrochloride

Signal word Danger
Pictogram(s)
ghs
Skull and Crossbones
Acute Toxicity
GHS06
GHS Hazard Statements H300:Acute toxicity,oral
H336:Specific target organ toxicity,single exposure; Narcotic effects

Computed Descriptors for Methadone hydrochloride

Related products of tetrahydrofuran

You may like

  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 88491-46-7 98%
    88491-46-7 98%
    88491-46-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.